NCT06563596 2026-02-19
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
10 trialsNCT07418190 2026-02-18
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06350318 2026-02-05
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06492837 2026-01-28
FIL_MOZART
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05389293 2025-12-31
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07126678 2025-08-17
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT06859008 2025-08-05
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT06959732 2025-05-07
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06471738 2024-07-18
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Chinese PLA General Hospital
Phase 2 Recruiting